Company intelligence / Profile preview

Omicron Pharma

Surat, Gujarat, India

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Omicron Pharma primarily operates as a generic pharmaceutical manufacturer and exporter. However, in collaboration with academic institutions, it has supported clinical trials for Vitamin K2 (Menaquinone-7) focused on reducing arterial stiffness and aortic valve calcification. Results from the KING trial and others indicate a role for their Vitamin K2 products in modulating dephosphorylated-uncarboxylated Matrix Gla protein (dp-ucMGP) levels.

Therapeutic areas: ImmunologyEndocrinologyCardiovascularNeurologyInfectious Diseases
Modalities: Small moleculePeptidesNutraceutical
Industry: Biotech

Partnerships

Gnosis by LesaffreNattopharma ASA

Beyond the preview

Go deeper on Omicron Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Omicron Pharma.

Explore the full profile